Teva Bulks Up Biopharma With $400 Million CoGenesys Acquisition
Executive Summary
Teva Pharmaceuticals will acquire the privately held biopharma CoGenesys for $400 million in an effort to strengthen its biogenerics position, the company announced Jan. 22
You may also be interested in...
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Merck’s Ambitious Plans For Follow-On Biologics
Merck outlined ambitious plans for launching and growing a follow-on biologics business during its annual business briefing Dec. 9
Teva R&D Spending Target Raised To 7.5% Of Sales
Teva Pharmaceuticals will boost research and development spending this year toward a new goal of 7.5 percent of sales, company executives announced during the firm's fourth quarter earnings call Feb. 12